Paul Hastings Advises Orchestra BioMed on Financing Transactions

Paul Hastings LLP advised Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, in connection with several financing transactions, including its underwritten public offering of shares of common stock and pre-funded warrants, concurrent private placement transactions and royalty financing transactions with Ligand Pharmaceuticals Incorporated and Medtronic Inc. The transactions are expected to raise gross proceeds of over $110 million. Piper Sandler and TD Cowen acted as joint book-running managers for the underwritten public offering.

The Paul Hastings team was led by Emerging Growth Companies partner Sam Waxman, Securities and Capital Markets partner Yariv Katz and Structured Credit partner Richard Davis, and included partner Robert Hopkins; of counsel Keith Pisani, Regina Gromen and Shai Marshall; and associates Chris Guerin, Matt Schob, Jiajun Lu, Harry Townsend and Kamal Qteishat.

More details about the transactions can be found here and here.

About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.